Daily Endocrinology Research Analysis
Three high-impact endocrinology papers strengthen the cardio-renal-hepatic benefits of incretin-based therapy. Semaglutide reduced major kidney, cardiovascular, and mortality outcomes in T2D with CKD irrespective of mineralocorticoid receptor antagonist use, while GLP-1 receptor agonists improved MASH histology in RCTs and were associated with lower liver disease progression and MACE/death in a 58,157-pair real-world cohort.
Summary
Three high-impact endocrinology papers strengthen the cardio-renal-hepatic benefits of incretin-based therapy. Semaglutide reduced major kidney, cardiovascular, and mortality outcomes in T2D with CKD irrespective of mineralocorticoid receptor antagonist use, while GLP-1 receptor agonists improved MASH histology in RCTs and were associated with lower liver disease progression and MACE/death in a 58,157-pair real-world cohort.
Research Themes
- Incretin therapies and organ protection in T2D and CKD
- GLP-1 receptor agonists for MASLD/MASH histologic improvement
- Real-world cardio-hepatic outcomes with GLP-1RA vs DPP4 inhibitors
Selected Articles
1. Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
In this prespecified secondary analysis of the FLOW RCT, semaglutide reduced the primary kidney outcome by 49% in MRA users and 21% in nonusers, with no heterogeneity for MACE or all-cause mortality. Albuminuria and eGFR decline improved similarly regardless of baseline MRA use, and safety was comparable.
Impact: Clarifies that semaglutide’s kidney and cardiovascular benefits in T2D with CKD are robust to concurrent MRA therapy, supporting broader use in complex polypharmacy settings.
Clinical Implications: Semaglutide can be initiated or continued in T2D+CKD patients irrespective of MRA co-therapy to reduce kidney failure progression, MACE, and mortality. Monitoring for albuminuria and eGFR trends remains appropriate without needing to modify based solely on MRA status.
Key Findings
- Primary kidney outcome reduced by 49% with semaglutide in MRA users (HR 0.51, 95% CI 0.30–0.86) and by 21% in nonusers (HR 0.79, 95% CI 0.68–0.92); no significant interaction (P=0.12).
- No heterogeneity for effects on MACE and all-cause mortality across MRA strata (P-interaction > 0.7).
- At 104 weeks, albuminuria and eGFR decline improved similarly regardless of baseline MRA use; safety profile comparable between subgroups.
Methodological Strengths
- Prespecified subgroup analysis within a randomized, placebo-controlled outcomes trial.
- Consistent multi-endpoint assessment (kidney composite, MACE, mortality) with large non-MRA subgroup.
Limitations
- Subgroup analysis; not powered for interaction testing.
- Baseline MRA use was predominantly spironolactone; finerenone exposure minimal, limiting generalizability across MRAs.
Future Directions: Head-to-head and factorial designs evaluating GLP-1RA with contemporary MRAs (e.g., finerenone) and SGLT2 inhibitors, assessing additive or synergistic kidney and CV benefits.
OBJECTIVE: In the Evaluate Renal Function With Semaglutide Once Weekly (FLOW) trial, semaglutide reduced the risk of major kidney and cardiovascular (CV) outcomes and all-cause mortality in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). This prespecified analysis assessed the effects of semaglutide on kidney, CV, and mortality outcomes by baseline mineralocorticoid receptor antagonist (MRA) use. RESEARCH DESIGN AND METHODS: Participants were randomized to once-weekly subcutaneous semaglutide 1.0 mg or placebo. The primary kidney outcome was a composite of time to first persistent ≥50% eGFR reduction from baseline, kidney failure, or death from kidney/CV causes. Baseline MRA was predominantly spironolactone; finerenone was only available after recruitment ended. RESULTS: Effects were analyzed by baseline MRA use (n = 257 [136 in the semaglutide group and 121 in the placebo group]) and nonuse (n = 3,276 [1,631 in the semaglutide group and 1,645 in the placebo group]). Semaglutide reduced the risk of the primary kidney outcome by 49% (59 events; hazard ratio [HR] 0.51 [95% CI 0.30, 0.86]) and 21% (682 events; HR 0.79 [95% CI 0.68, 0.92]; P-interaction = 0.12) versus placebo in MRA and non-MRA subgroups, respectively. There was no heterogeneity, favoring the effects of semaglutide on major adverse CV events (MACE) and all-cause mortality in both MRA subgroups (P-interaction > 0.7). Albuminuria at 104 weeks was reduced from baseline with semaglutide by 15% (95% CI -41, 31) in MRA users and 33% (26, 39) in nonusers versus placebo (P-interaction = 0.22). Estimated glomerular filtration rate decline was similarly reduced with semaglutide (P-interaction = 0.71). The safety profile of semaglutide was comparable between subgroups. CONCLUSIONS: In participants with T2D and CKD, consistent benefits of semaglutide on major kidney outcomes, MACE, and all-cause mortality were observed regardless of baseline MRA use.
2. Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials.
Across 13 RCTs (n=1811), GLP-1RAs—particularly semaglutide 2.4 mg/week—achieved higher rates of MASH resolution without worsening fibrosis and reduced liver fat on MRI-based measures over up to 72 weeks. Evidence supports GLP-1RAs as therapeutic options for MASLD/MASH, pending confirmation of effects on hard liver outcomes.
Impact: Provides synthesized RCT evidence that GLP-1RAs improve histologic and imaging endpoints in MASH, guiding treatment considerations amid emerging metabolic liver therapeutics.
Clinical Implications: In MASH with moderate-to-advanced fibrosis, GLP-1RAs (e.g., semaglutide 2.4 mg weekly) may be considered to achieve histologic resolution and reduce liver fat, alongside weight loss and cardiometabolic benefits. Long-term monitoring is needed until effects on cirrhosis and decompensation are established.
Key Findings
- Meta-analysis of 13 phase 2/3 RCTs (n=1811) showed GLP-1RAs significantly increased MASH resolution without worsening fibrosis versus placebo (pooled OR 3.48, 95% CI 2.69–4.51).
- Trials included both biopsy-proven (n=4) and MR-based diagnosed MASLD/MASH (n=9), with consistent reductions in liver fat content on MR techniques.
- Benefits were observed over treatment durations up to 72 weeks and were not contingent on baseline diabetes status.
Methodological Strengths
- Random-effects meta-analysis restricted to randomized controlled trials.
- Inclusion of both histology-based and MRI-based endpoints enhances generalizability.
Limitations
- Heterogeneity in diagnostic criteria (biopsy vs MR) and treatment durations up to 72 weeks; long-term clinical outcomes (cirrhosis, decompensation) not established.
- Class effects vs agent-specific effects (e.g., semaglutide 2.4 mg) cannot be fully disentangled.
Future Directions: Large, long-duration outcome RCTs to determine effects on cirrhosis progression, decompensation, transplant-free survival, and mortality; head-to-head comparisons with emerging MASH agents.
BACKGROUND/AIMS: There is uncertainty regarding the hepatic efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis (MASH). We performed a meta-analysis of randomised controlled trials (RCTs) to examine the efficacy of GLP-1RAs in treating MASLD or MASH. METHODS: We systematically searched three electronic databases from inception until April 2025 to identify RCTs examining the efficacy of GLP-1RAs for the treatment of MASLD or MASH. The outcome measures included MASH resolution without worsening of fibrosis or improvement in at least one stage of fibrosis without worsening of MASH, along with reductions in liver fat content measured using magnetic resonance-based techniques. Meta-analysis was conducted using random-effects models. RESULTS: We identified 13 phase 2 or phase 3 RCTs (1811 participants). These trials diagnosed MASLD or MASH through liver biopsy (n = 4) or magnetic resonance-based techniques (n = 9). Regardless of diabetes status, among individuals with MASH and moderate-to-advanced fibrosis, GLP-1RAs (especially semaglutide 2.4 mg/week) for up to 72 weeks were superior to placebo in achieving MASH resolution (n = 3 RCTs; pooled random-effects odds ratio 3.48, 95% CI 2.69-4.51; I CONCLUSIONS: GLP-1RAs are a promising treatment option for MASLD or MASH. Further research is needed to evaluate the long-term effects of GLP-1RAs on liver-related clinical events.
3. Association of GLP1-receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes.
In a large VA propensity-matched cohort (58,157 pairs), GLP-1RA initiation was associated with lower liver disease progression (OR 0.86) and substantially fewer MACE/deaths (OR 0.72) compared with DPP4 inhibitors. NNTs were 109 for preventing liver progression and 27 for preventing MACE/death.
Impact: Provides robust real-world evidence that GLP-1RAs may confer both hepatic and cardiovascular protection in MASLD with diabetes, informing therapeutic selection beyond glycemic control.
Clinical Implications: For patients with diabetes and hepatic steatosis, GLP-1RAs may be preferred over DPP4 inhibitors when aiming to reduce liver disease progression and MACE/death, complementing lifestyle and multisystem risk management.
Key Findings
- Propensity-matched 58,157 GLP-1RA vs 58,157 DPP4i initiators showed lower liver disease progression with GLP-1RA (6.1% vs 7.0%; OR 0.86, 95% CI 0.82–0.90).
- GLP-1RA use was associated with fewer MACE/deaths (11.1% vs 14.7%; OR 0.72, 95% CI 0.70–0.75).
- Number needed to treat: 109 to prevent one liver disease progression and 27 to prevent one MACE/death.
Methodological Strengths
- Very large national cohort with rigorous propensity score matching on 73 baseline characteristics.
- Clinically meaningful co-primary outcomes spanning hepatic and cardiovascular events.
Limitations
- Observational design subject to residual confounding and channeling bias despite matching.
- Generalizability may be limited (veteran population, predominantly male).
Future Directions: Prospective pragmatic trials comparing GLP-1RAs to other antidiabetic classes in MASLD, with adjudicated hepatic and CV endpoints and diverse populations.
AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease in the United States. MASLD can progress to liver cirrhosis and is associated with an increased risk of major acute cardiovascular events (MACE). This study aimed to examine the association of glucagon-like peptide-1 receptor agonists (GLP1-RA) use with liver disease progression, MACE, and death from any cause among people with hepatic steatosis. MATERIALS AND METHODS: This retrospective cohort study using national data from the Department of Veteran Affairs included people with non-alcoholic hepatic steatosis who initiated either GLP1-RA or dipeptidyl-peptidase-4 inhibitor (DPP4i) between 1 October 2005 and 30 September 2021. Primary outcomes were: (1) liver disease progression and (2) MACE and death from any cause (MACE/death). GLP1-RA users and DPP4i users were propensity score matched on 73 baseline characteristics. RESULTS: We matched 58 157 pairs of GLP1-RA and DPP4i users. GLP1-RA users had less liver disease progression (6.1%) compared with DPP4i users (7.0%), odds ratio (OR): 0.86; 95% confidence interval (95% CI): 0.82-0.90 and a lower risk of MACE/death (11.1% vs. 14.7%, respectively), OR: 0.72; 95% CI: 0.70-0.75. The number needed to treat to prevent one additional liver disease progression and MACE/death was 109 and 27 people, respectively. CONCLUSIONS: Among people with diabetes and hepatic steatosis, GLP1-RA use was associated with a lower risk of liver disease progression and a lower risk of MACE/death compared to DPP4i use. In people with MASLD, a holistic approach that seeks to lower MACE/death, beyond lowering liver disease progression alone, should be prioritised.